ReNerve

ASX Announcement

19 November 2026

Release of Securities from Escrow

ReNerve Limited (ASX: RNV, "ReNerve" or "the Company"), an Australian medical device company developing innovative products for peripheral nerve injury (PNI) repair, advises, in accordance with ASX Listing Rule 3.10A, that the following fully paid ordinary shares (Shares) will be released from escrow on 25 November 2026:

Security code	Description	Number of shares
RNVESC24	Mandatory escrow shares - 24 months from quotation	31,255,716
RNVESC24V	Voluntary escrow shares - 24 months from quotation	8,680,010
Total		**39,935,726**

Certain number of the Shares being released from escrow are held by current and former directors of the Company and/or their associated entities, with the balance held by other security holders.

The Company acknowledges that this notice is being provided outside the timeframe prescribed by ASX Listing Rule 3.10A, which requires notice to be given to ASX at least 10 business days before securities are released from escrow. The delay arose from an inadvertent administrative oversight.

The Company has reviewed its internal procedures and implemented measures designed to ensure that future notifications are made within the applicable timeframes.

The Company acknowledges its obligations under the ASX Listing Rules, including its continuous disclosure obligations under Listing Rule 3.1 and its obligation to comply with applicable notification timeframes.

The release from escrow does not involve the issue of any new securities and will not alter the Company's issued share capital.

ENDS -

This announcement has been approved for release by the Company's Board of Directors.

For further information and enquiries, please contact:

Dr Julian Chick
CEO & Managing Director
ReNerve Ltd
+61 (03) 9482 3940
info@renerve.com.au

Matthew Wright
Investor & Media Relations
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au

About ReNerve Limited (ASX:RNV)

ReNerve Limited (ASX:RNV) is an Australian medical device company developing products for peripheral nerve injury (PNI) repair. Founded by a neurosurgeon and medtech researchers, ReNerve is focused on ready-to-use solutions designed to support peripheral nerve surgery and improve patient outcomes. The Company's lead product is the FDA-cleared NervAlign® Nerve Cuff, complemented by the Empliq® range of human tissue products for surgical and wound-care applications. ReNerve's product pipeline includes the NervAlign® Nerve Conduit and the NervAlign® Nerve Guide Matrix, currently in development. ReNerve products are commercialised in the United States, New Zealand, Hong Kong, Thailand, Malaysia, Indonesia, the Philippines and India. For more information visit [www.renerve.com.au].